CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report

被引:0
作者
Young, Robin J. [1 ]
Chowdry, Joanna E. [2 ]
Cochonneau, Denis [3 ]
Heymann, Dominique [2 ,3 ,4 ]
机构
[1] Sheffield Teaching Hosp NHS Fdn Trust, Weston Pk Canc Ctr, Whitham Rd, Sheffield S10 2SJ, England
[2] Univ Sheffield, Sch Med & Populat Hlth, Sheffield S10 2RX, England
[3] Inst Cancerol Ouest, Tumour Heterogene & Precis Med Lab, F-44805 St Herblain, France
[4] Nantes Univ, CNRS, UMR 6286, F-44322 Nantes, France
关键词
Circulating tumour cells; soft tissue sarcoma; metastasis;
D O I
10.20517/cdr.2024.149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Circulating tumour cells (CTCs) can be detected in peripheral blood using their physical properties (increased size and less deformable than normal circulating blood cells) or using cell surface markers. The study of these CTCs should provide important insights into tumour biology, including mechanisms of drug resistance. We performed a pilot study (IRAS ID: 235459) to evaluate if CTCs could be isolated from peripheral blood samples collected from soft tissue sarcoma (STS) patients. Methods: We used a combined approach that first enriched samples for CTCs using a microfluidic cassette via ParosrtixTMPR1, and then sorted cells stained for vimentin and cytokeratin using the DEPArrayTM. The total circulating cell-free DNA (cfDNA) level was also analysed. Data were correlated with clinical parameters. Results: 13 patients were recruited to this study: 7 patients with localised disease and 6 patients with metastatic disease. CTCs exhibited a high heterogeneity based on their expression of mesenchymal and epithelial markers. There was no significant difference in the number of CTCs between patients with localised versus metastatic disease. We observed no correlation between CTC numbers and cfDNA; however, the number of CTCs did correlate with primary tumour size. Conclusion: The present study demonstrates the presence of CTCs in STS patients with localised and advanced disease. Further and larger studies are needed to characterise STS CTCs and to evaluate their prognostic significance
引用
收藏
页数:9
相关论文
共 19 条
  • [1] Grunewald TG, Alonso M, Avnet S, Et al., Sarcoma treatment in the era of molecular medicine, EMBO Mol Med, 12, (2020)
  • [2] Hayes AJ, Nixon IF, Strauss DC, Et al., UK guidelines for the management of soft tissue sarcomas, Br J Cancer, (2024)
  • [3] Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D., The challenges of detecting circulating tumor cells in sarcoma, Front Oncol, 6, (2016)
  • [4] Lin D, Shen L, Luo M, Et al., Circulating tumor cells: biology and clinical significance, Signal Transduct Target Ther, 6, (2021)
  • [5] Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D., Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?, Drug Discov Today, 24, pp. 763-772, (2019)
  • [6] Satelli A, Mitra A, Cutrera JJ, Et al., Universal marker and detection tool for human sarcoma circulating tumor cells, Cancer Res, 74, pp. 1645-1650, (2014)
  • [7] Hvichia GE, Parveen Z, Wagner C, Et al., A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells, Int J Cancer, 138, pp. 2894-2904, (2016)
  • [8] Le MN, Smith KA, Dopico PJ, Et al., Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas, Sci Rep, 14, (2024)
  • [9] Mu H, Zuo D, Chen J, Et al., Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis, Cancer Biol Med, 19, pp. 1397-1409, (2022)
  • [10] Vincenzi B, Rossi E, Zoccoli A, Et al., Circulating tumor cells in soft tissue sarcomas patients, Ann Oncol, 23, (2012)